Apertor Pharmaceuticals

At Apertor we have developed a new class of therapeutics to address one of the toughest challenges in drug discovery — selective disruption of disease-causing protein-protein interactions (PPIs). Apertor’s Interceptors are designed to selectively disrupt protein complexes via proximity induction by recruiting an abundantly expressed protein naturally found in cancerous cells patient’s own proteins to safely and effectively block PPIs. Using our synthetic biology platform technology to invent and develop proprietary Interceptors, Apertor’s robust pipeline is unlocking new treatment possibilities for cancer patients.